Bryan Ball Sells 26,389 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Key Points

• Bryan Ball sold 26,389 shares on April 13 at an average price of $3.46 (about $91,306), part of recent total sales of 177,279 shares for roughly $635,055, reducing his position by 5.11% to 489,566 shares (≈$1.69M).
• The sales were disclosed in an SEC filing and were made to cover tax withholding obligations tied to the vesting of equity awards.
• Whitehawk (WHWK) traded down about 2.5% to $3.90 on above-average volume; analysts are mixed (2 Buy, 1 Hold, 1 Sell) with a consensus Hold and an average price target of $6.50.

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) insider Bryan Ball sold 26,389 shares of the stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $3.46, for a total transaction of $91,305.94. Following the transaction, the insider owned 489,566 shares in the company, valued at approximately $1,693,898.36. This trade represents a 5.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bryan Ball also recently made the following trade(s):

• On Tuesday, April 14th, Bryan Ball sold 92,460 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.64, for a total transaction of $336,554.40.
• On Friday, April 10th, Bryan Ball sold 6,596 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.43, for a total transaction of $22,624.28.
• On Thursday, April 9th, Bryan Ball sold 50,000 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.57, for a total transaction of $178,500.00.
• On Monday, March 2nd, Bryan Ball sold 1,834 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.31, for a total transaction of $6,070.54.

Whitehawk Therapeutics Stock Down 2.5%

WHWK traded down $0.10 during trading on Wednesday, hitting $3.90. The company's stock had a trading volume of 316,487 shares, compared to its average volume of 187,321. Whitehawk Therapeutics, Inc. has a one year low of $1.39 and a one year high of $4.48. The firm has a market cap of $184.08 million, a PE ratio of 8.30 and a beta of 0.57. The business's 50 day simple moving average is $3.40 and its 200-day simple moving average is $2.76.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.21.

Analysts Set New Price Targets

WHWK has been the topic of several recent research reports. Oppenheimer initiated coverage on shares of Whitehawk Therapeutics in a research report on Thursday, February 5th. They issued an "outperform" rating and a $6.00 price target on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. JonesTrading started coverage on shares of Whitehawk Therapeutics in a research note on Monday, December 22nd. They issued a "buy" rating and a $7.00 price objective for the company. Finally, Wall Street Zen cut shares of Whitehawk Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $6.50.

Institutional Trading of Whitehawk Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Avoro Capital Advisors LLC purchased a new position in Whitehawk Therapeutics during the third quarter valued at $5,414,000. Suvretta Capital Management LLC purchased a new position in Whitehawk Therapeutics during the third quarter valued at $7,030,000. Ally Bridge Group NY LLC purchased a new position in Whitehawk Therapeutics during the third quarter valued at $1,554,000. Peapod Lane Capital LLC purchased a new position in Whitehawk Therapeutics during the third quarter valued at $577,000. Finally, Dimensional Fund Advisors LP purchased a new position in Whitehawk Therapeutics during the third quarter valued at $84,000. 52.08% of the stock is owned by hedge funds and other institutional investors.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.